Biocon Limited has informed the Exchange regarding a press release dated March 27, 2024, titled "Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.".
Biocon Limited has informed the Exchange regarding a press release dated March 27, 2024, titled "Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.".